Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nasal cavity drop for treating diabetes and preparation method thereof

A technology of diabetes and nasal cavity, which is applied in the field of nasal cavity drops for the treatment of diabetes and its preparation, which can solve the problems of environmental pollution, patient pain, half-life of less than 2 minutes, etc., and achieve the effect of avoiding potential safety hazards, pain and inconvenience

Inactive Publication Date: 2011-03-23
南京凯瑞尔纳米生物技术有限公司
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, GLP-1 will be rapidly degraded and inactivated by dipeptidyl peptidase IV (dipeptidy I peptidase IV, DPP IV) in vivo, and its half-life is less than 2 minutes
2. Purulent infection at the injection site caused by incomplete disinfection of instruments, pollution of the surrounding environment, and incomplete disinfection of the injection site
3. Nerve paralysis or even death caused by improper injection
Moreover, diabetes is a chronic disease that requires long-term administration, so commercially available products bring continuous pain, inconvenience and safety hazards to patients during use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 2

Embodiment 2

[0025] Example 3

Embodiment 3

[0027] Experimental animals:

[0028] SD rats, 180-200g, male, 8

[0029] Experimental drug:

[0030] Test group: the nasal cavity drops obtained in Example 2, the exenatide concentration in the nasal cavity drops was 16 mg / ml.

[0031] Control group: exenatide was diluted with water for injection, and the concentration of the effective drug exenatide after dilution was 16 mg / ml.

[0032] experimental method:

[0033] The experimental rats were reared for 3 days in advance, and fasted for 12 hours the day before the test.

[0034] Divide the rats into four parallel groups A, B, C, and D, with 2 rats in each group, wherein, groups A, B, and C are the test groups, and group D is the control group, and each group is given nasal drops of 5 μl / rat. The dosage is 100μg / 200g. In each group, 0.3 ml of orbital blood was collected from one mouse at 5, 10, 20, and 30 minutes after administration, and the blood was centrifuged at 4°C and 3,000 rpm for 10 minutes to collect the upper s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses a nasal cavity drop for treating diabetes and a preparation method. The nasal cavity drop comprises solvent and accessories, and is characterized in that the solvent contains a compound of calcium phosphate nano particles and exenatide, the weight ratio of the calcium phosphate nano particles to the exenatide in the compound is 1-10:0.1-10, and the content of the exenatidein the solvent is 0.01 to 0.5 milligram per milliliter. The preparation method for the nasal cavity drop comprises the following steps: mixing aqueous solutions of calcium salt, phosphate, citrate and exenatide to form the compound of the calcium phosphate nano particles and the exenatide, adding the accessories which are frequently used for aqueous agent into the mixture, detecting and adjustingthe pH of the solution, and finally forming the nasal cavity drop, wherein the weight ratio of the calcium phosphate nano particles to the exenatide in the compound is 1-10:0.1-10, and the content ofthe diluted exenatide in the solvent is 0.01 to 0.5 milligram per milliliter.

Description

technical field [0001] The invention relates to a nasal cavity drop and a preparation method thereof, in particular to a nasal cavity drop containing exenatide for treating diabetes and a preparation method thereof. Background technique [0002] Diabetes is a common metabolic endocrine disease. Because of its high morbidity, mortality and disability rate, it seriously endangers human health, and it is increasingly concerned by the medical community. From the perspective of clinical incidence, most of them are type II diabetes, and its clinical symptoms are that the glucose content in blood and urine exceeds the normal range. Blood sugar levels are mainly regulated by insulin and glucagon. Glucagon accelerates the breakdown of glycogen through a series of reactions. Increase the concentration of glucose in the body, on the contrary, insulin accelerates the synthesis of glycogen and reduces the concentration of blood sugar. In the body, glucagon is first synthesized as a pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/08A61K38/17A61K47/02A61P3/10
Inventor 河清冯振卿管晓虹袁伟民冯鲁中张学智
Owner 南京凯瑞尔纳米生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products